At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
Skin Biopsy of Skin Rash Secondary to EGFRI Useprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Histological Characterization and Differentiation of Rash From Other EGFR Inhibitors
In Brief
An observational study evaluating Skin Biopsy of Skin Rash Secondary to EGFRI Use for Skin Rash. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Rash
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedJul 2008
Primary CompletionAug 2010
TodayJul 2026
First PostedJul 3, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.0 years ago
Interventions
Skin Biopsy of Skin Rash Secondary to EGFRI Useprocedure
Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.